London, December 3, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Curve Therapeutics (“Curve”) and is pleased to announce the placement of Rab Prinjha, PhD, as Chief Research and Development (R&D) Officer.Curve Therapeutics is a private biotechnology company pioneering a revolutionary mammalian cell-based, functional drug discovery platform to address intracellular disease targets. Its mission is to improve patient outcomes by discovering…
London, United Kingdom, 29th November 2024 / One Nucleus
The 24th Life Science networking conference, organised by membership organisation One Nucleus, will be hosted at the Royal Society of Medicine, on Wednesday 4th December.
In a ‘first’ this year, Genesis is being co-located with Life Science Nation’s annual ‘Redefining Early-Stage Investments’ conference, connecting companies developing drugs, devices, digital health and diagnostic products with a global network of capital investors and licensing partners.
Delegates can register separately for both events, taking advantage…
The first half of 2024 has been an active year for M&A’s in the life sciences industry. The overall data reflects significant quarterly fluctuations in the total value and count of M&A deals within the life sciences sector from 2022 to mid-2024, highlighting shifting market priorities and potential external influences such as regulatory changes or macroeconomic factors.
For detailed information and statistics on the latest M&A activity in the biotechnology and digital health sectors, read the Life Sciences M&A Report. Published biannually by Venture Valuation, the report is…
The last People Pathways newsletter of 2024 is available to read now! You have the chance to be one of the first to secure a place on our 2025 courses and be part of the excellent pool of delegates we have already trained.Any queries, please email the team on training@onenucleus.com
New report reveals how groundbreaking research at the Campus is delivering major gains for UK economic growth and job creation
Cambridge, UK, 28th November 2024: A new independent report evaluating the economic and scientific impact of the Babraham Research Campus has revealed significant contributions not only to the UK and global life sciences sector, but to the local Cambridge and wider UK economy.
The independent evaluation, carried out between late 2023 and early 2024 by a team headed up by Professor Pete Tyler and Dr Andy Cosh, updates the findings from 2019 and captures a period…
4 December | 1 Wimpole Street, London
Will you be there for this unique opportunity to discuss the trends, best practice and future expectations of the Life Science sector? On Wednesday 4 December 2024, Genesis will assemble 300 life science influencers and integrate with the inaugural RESI London event to increase the opportunities to connect innovation, innovators and investors. See which companies are attending Genesis alone.
How will the Industry Evolve in 2025?The Keynote programme is packed with those driving business…
London, November 26, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Entia and is pleased to announce the placement of Timothy Broke-Smith as Senior Vice President of Partnerships.Working at the frontiers of remote patient monitoring and predictive analytics, Entia has combined novel at-home blood testing technology and digital solutions to deliver personalized insights into cancer patients’ journeys through treatment.The company’s flagship innovation –…
Europa Biosite is pleased to announce the acquisition of AMSBIO, a premier supplier of life science products and services, with expertise in the areas of biospecimens, stem cell research, 3D cell culture, glycobiology, and molecular biology. Headquartered in Oxford, UK, and with offices in both the USA and the Netherlands, AMSBIO serves life science researchers across Europe and throughout North America.
AMSBIO is an important strategic addition to Europa Biosite, further expanding the group’s offering in three high growth areas: biospecimens, stem cell research and regenerative medicine, as…
A new industry briefing note developed by Pioneer Group in collaboration with the UK chemicals sector community highlights the urgent need for the sector to transition to a more sustainable, circular economy.
The paper, developed at a ‘Pioneer Presents’ workshop held at the Wilton Centre, Tees Valley, earlier this year, outlines the environmental challenges associated with the sector’s current reliance on fossil resources, the potential of sustainable carbon feedstocks, and the significant actions required to transform the UK chemicals industry.
Over 40 representatives from industry, academia…
London, November 21, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with Solu Therapeutics (Solu) and is pleased to announce the placement of Sergio Santillana, MD, MSc, MBA, as Chief Medical Officer (CMO).Solu Therapeutics is a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas.As CMO, Dr. Santillana will oversee strategic direction and execution in Solu’s clinical development programs, leading efforts and…